Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

What this dramatic movement in obesity therapy means for patients in Europe.
How these two FDA-submitted drugs could address this major healthcare need.
How a single change at the FDA could lead to major improvements for patients and the healthcare system.
A clinical trial takes a new approach to type 1 prevention research.
Complete with a savings card, a patient coaching program, and more!
When could it reach patients?
Submitted to the FDA and could be approved this year.
Current trial results show that obese patients using Contrave are about 41% less likely to experience any major heart event (e.g. heart attack, strokes, or heart-related...
How will a new drug fare in a 4,000-patient, four-year study?
First-ever SGLT-2/DPP-4 inhibitor drug, will this combination cut costs for patients?
How this “disease interception” strategy could transform our knowledge of type 1 diabetes.
How a major research study is challenging an outdated FDA restriction.
Sanofi and MannKind announce Afrezza's official US launch.
What happens when these two unique drugs are taken together?
Our deep dive on a new therapy now available in Europe – the benefits, risks, and when it might come to the US.
Twitter summary: FDA approves Novo Nordisk’s chronic weight management drug Saxenda, another option to help treat #obesity On December 23, the FDA approved Novo Nordisk’...
Twitter Summary: Lilly’s Trulicity, a once-weekly GLP-1 agonist available in US, has now been approved in Europe On November 25, Eli Lilly’s Trulicity (dulaglutide) was... Identifier: NCT00920582 This study is currently recruiting patients recently diagnosed with type 1 diabetes to investigate the efficacy of teplizumab...
Twitter summary: JAMA study shows that metformin is safest first-line therapy for type 2 diabetes – future GRADE study to show best second-line therapy The journal JAMA...
Twitter summary: @LillyDiabetes launches Trulicity in the US – first ready-to-use once-weekly GLP-1, available w/savings program for commercially insured On November 10...